Complete resolution of severe chronic active Epstein-Barr virus infection by cultured, activated donor T lymphocyte infusion after nonmyeloablative stem cells allografting.
A patient with chronic active Epstein-Barr virus (EBV) infection was treated by allogeneic SCT from an HLA-identical sibling donor, using a nonmyeloablative regimen. Even on day 70, mixed chimerism remained together with a quite high viral load. On days 76 and 90, donor lymphocytes were infused after short-term culture with OKT3 plus recombinant IL-2. At 8 days after the last dose, all hematopoietic cells were shown to be donor-type dominant; thereafter, the viral load started to decrease and finally disappeared. Anti-mHA-specific CTLs were generated in vitro, which were shown to be effective in eradicate viral-infected recipient T lymphocytes.
Yoshiba
F
F
Department of Hematology and Oncology, Tokai University School of Medicine, Kanagawa, Japan.
Hagihara
M
M
Tazume
K
K
Ogawa
Y
Y
Kishi
K
K
Higuchi
A
A
Kato
S
S
Hotta
T
T
D000328:Adult; D002478:Cells, Cultured; D002908:Chronic Disease; D020031:Epstein-Barr Virus Infections / Q000628:therapy*; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D008213:Lymphocyte Activation / Q000276:immunology; D017710:Lymphocyte Transfusion / Q000379:methods*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology / Q000637:transplantation*; D018183:Transplantation Chimera; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D019562:Viral Load